Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
02/2005
02/24/2005WO2004075923A3 Polymer-factor viii moiety conjugates
02/24/2005WO2004073656A3 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
02/24/2005WO2004056386A3 Nucleic acids involved in blood-brain barrier control
02/24/2005WO2004010997A8 Sustained-release tablet composition of pramipexole
02/24/2005WO2004009064A8 Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means
02/24/2005WO2003105661A3 Materials with both bioadhesive and biodegradable components
02/24/2005WO2003093299A3 Insulin-associated peptides with effects on cerebral health
02/24/2005WO2003061362A3 Methods and compositions for treating polycystic ovary syndrome
02/24/2005WO2003059273A3 Antibody-avidin fusion proteins as cytotoxic drugs
02/24/2005WO2003037400A3 Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
02/24/2005US20050043481 Material consisting of at least a biodegradable polymer and cyclodextrins
02/24/2005US20050043457 microfuidic osmotic pumps comprising flexible containers encapsulated by solutes, semipermeable membranes encapsulating the solutes, seals and bores; drug delivery devices
02/24/2005US20050043399 Dimeric compounds and their use as anti-viral agents
02/24/2005US20050043380 Composition for treatment of malignant tumors
02/24/2005US20050043377 Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition
02/24/2005US20050043375 Solid preparation containing single crystal form
02/24/2005US20050043286 Use of an ascomycin for the treatment of blepharitis
02/24/2005US20050043285 Formulation
02/24/2005US20050043284 containing an anti-inflammatory and anti-allergic compound of the androstane series
02/24/2005US20050043283 comprising a steroidal hormone (eg androgen) or anti-inflammatory agent (eg triamcinolone, hydrocortisone ); for cosmetics and dermatology
02/24/2005US20050043271 Heparin-containing ophthalmic agent
02/24/2005US20050043228 Glp-1 formulations with protracted time action
02/24/2005US20050043225 Pharmaceutical formulation
02/24/2005US20050043224 Administering to patient a pharmaceutical preparation comprising at least one chemoprotective inducing agent and a vehicle for delivering chemoprotective inducing agent to cells lining hair follicles, in an amount and for a time effective to reduce or prevent hair loss
02/24/2005US20050043215 Complex drug delivery composition and method for treating cancer
02/24/2005US20050042753 Drug delivery compositions
02/24/2005US20050042680 Single chain antigen-binding polypeptides for polymer conjugation
02/24/2005US20050042471 durable, stronger, more ergonomic, better-looking than purely stonecast products eg housewares & commercial ornamental articles
02/24/2005US20050042304 Novel substituted benzimidazole dosage forms and method of using same
02/24/2005US20050042303 Therapeutic protocols
02/24/2005US20050042299 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
02/24/2005US20050042295 Anti-angiogenic compositions and methods of use
02/24/2005US20050042294 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
02/24/2005US20050042293 Mixture of hydrophobic drug and water soluble polymer; biodegradable insert
02/24/2005US20050042280 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
02/24/2005US20050042279 Pharmaceutical formulation comprising more than 15% tamoxifen
02/24/2005US20050042274 Compounds and compositions for delivering active agents
02/24/2005US20050042273 Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties
02/24/2005US20050042268 Administering a hormone and penetration enhancer urea compound
02/24/2005US20050042266 Cyanoacrylate compositions containing anti-microbial agent
02/24/2005US20050042265 Composition for cutaneous repair and cicatrization comprising exclusively a true physical hydrogel of chitosan
02/24/2005US20050042249 Warming and nonirritating lubricant compositions and method of comparing irritation
02/24/2005US20050042248 Mixture of polyol and insulation agent; gelation; dysmenorrhea
02/24/2005US20050042241 Topical analgesic and/or antiinflammatory cream; bursitis, tendonitis; dimethyl sulfoxide and a mixture of pluronic gel and lecithin; allows the longer acting pain relievers ketoprofen and diphenhydramine to reach underlying inflamed tissues
02/24/2005US20050042237 Method for administering a spill resistant pharmaceutical system
02/24/2005US20050042236 Plant extract active as an immunostimulating agent
02/24/2005US20050042218 Vaccines for treating and/or preventing cancer, infections, autoimmune diseases, and/or allergies
02/24/2005US20050042216 Binding monoclonal, humanized, or fragment of antibody to human cell that expresses a protein; cancer
02/24/2005US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents
02/24/2005US20050042194 Semi-solid delivery vehicle and pharmaceutical compositions
02/24/2005US20050042182 Topical compositions of urea
02/24/2005US20050042173 Pharmaceuticals, cosmetics or nutraceuticals with a bioadhesive and plasticizer on a biodegradable support for transdermal or transmucosal application
02/24/2005US20050042171 Only once daily administration of an antispasmodic beta-2 adrenergic agonist and an antiinflammatory corticosteroid; inhalation; salmeterol xinafoate
02/24/2005DE19828273B4 Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren Transdermal therapeutic system containing hormones and crystallization inhibitors
02/24/2005CA2762015A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule
02/24/2005CA2576060A1 Macrolides containing oil-in-water emulsions
02/24/2005CA2535670A1 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
02/24/2005CA2535554A1 Methods for reducing astringency
02/24/2005CA2534897A1 Process of making flowable hemostatic compositions and devices containing such compositions
02/24/2005CA2534895A1 Hemostatic compositions containing sterile thrombin
02/24/2005CA2534629A1 Engineered proteases for affinity purification and processing of fusion proteins
02/24/2005CA2534298A1 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
02/24/2005CA2534028A1 Liquid, aqueous pharmaceutical composition of factor vii polypeptides
02/24/2005CA2532110A1 Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
02/24/2005CA2524737A1 Antibodies that immunospecifically bind to trail receptors
02/23/2005EP1508601A1 Cyanoacrylate compositions containing anti-microbial agent
02/23/2005EP1508332A1 Medicinal composition
02/23/2005EP1508331A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection
02/23/2005EP1508330A1 Inhalation capsules
02/23/2005EP1508329A1 Composition for an antifungal agent for suppressing fungal growth in an oral cavity
02/23/2005EP1507874A2 Compositions and processes for inhibiting gene expression using polynucleotides
02/23/2005EP1507860A2 Dynamic action reference tools
02/23/2005EP1507859A2 Fusion proteins of humanized g250 specific antibodies and uses thereof
02/23/2005EP1507851A1 Method for assembling sub units into capsoides
02/23/2005EP1507826A2 Amelioration of the development of cataracts and other opthalmic diseases
02/23/2005EP1507813A1 Fat binding using inter-polymer complex of glucosamine and polyacrylic acid
02/23/2005EP1507804A1 Active carbohydrate containing protecting reagents for chemical modifications, their production and use
02/23/2005EP1507794A2 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
02/23/2005EP1507781A2 Process for preparing maytansinol
02/23/2005EP1507765A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
02/23/2005EP1507755A2 Novel monofunctional polyethylene glycol aldehydes
02/23/2005EP1507562A1 Methods and compositions for radioimmunotherapy of brain and cns tumors
02/23/2005EP1507559A1 Delivery of microparticle-conjugated drugs for inhibition of stenosis
02/23/2005EP1507557A1 Methods and devices for targeting a site in a mammal and for removing species from a mammal
02/23/2005EP1507556A2 Calicheamicin derivative-carrier conjugates
02/23/2005EP1507550A1 Suicide tetramers comprising mhc class i and uses thereof
02/23/2005EP1507538A1 Norethindrone sustained release formulations and methods associated therewith
02/23/2005EP1507519A1 Medicament with delayed release of the active substance, containing 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
02/23/2005EP1507517A1 Microparticles bearing cells and active substances
02/23/2005EP1507516A1 Co-grinding process for the preparation of a ternary composition
02/23/2005EP1507515A2 Free-flowing, powdery composition containing alpha-liponic acid (-derivatives)
02/23/2005EP1507514A2 Controlled release compositions of estradiol metabolites
02/23/2005EP1507455A1 Antimicrobial envelopes
02/23/2005EP1313489B1 Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
02/23/2005EP1311280A4 Cell internalized peptide-drug conjugates
02/23/2005EP1207757B1 Ectoparasiticidal aqueous suspension formulations of spinosyns
02/23/2005EP1175224B1 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
02/23/2005EP1119350B1 Rar antagonists as male anti-fertility agents
02/23/2005EP0689454B2 Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
02/23/2005CN1585822A Polycistronic expression of antibodies